Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
作者信息
Guevara Carlos, Villa Eduardo, Rosas Carlos Silva, Diaz Violeta, Naves Rodrigo
机构信息
Faculty of Medicine, Hospital Clínico José Joaquín Aguirre, Universidad de Chile, Santos Dumont 999, Santiago, Chile.
Faculty of Medicine, Hospital Clínico José Joaquín Aguirre, Universidad de Chile, Santos Dumont 999, Santiago, Chile.
出版信息
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
Abstract
摘要
相似文献
1
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.在新冠疫情期间治疗多发性硬化症患者：评估专家建议。
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
2
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
3
COVID-19 will change MS care forever - No.新冠疫情将永远改变多发性硬化症的护理——不。
Mult Scler. 2020 Sep;26(10):1149-1151. doi: 10.1177/1352458520929971. Epub 2020 Jun 22.
4
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.冠状病毒病（COVID-19）大流行对多发性硬化症护理的影响。
Clin Neurol Neurosurg. 2020 Oct;197:106203. doi: 10.1016/j.clineuro.2020.106203. Epub 2020 Sep 2.
5
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.接受免疫抑制剂治疗的多发性硬化症患者：在整个新冠疫情范围内。
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
6
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.一名多发性硬化症患者在大流行期间开始使用奥瑞珠单抗治疗，感染新冠病毒后预后良好。
Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.
7
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.与 COVID-19 大流行期间多发性硬化症疾病修正治疗相关的基础生物学。
Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12.
8
COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.新冠疫情：智利一家多发性硬化症中心的经历
Mult Scler Relat Disord. 2020 Jul;42:102204. doi: 10.1016/j.msard.2020.102204. Epub 2020 May 16.
9
COVID-19 in MS: Initial observations from the Pacific Northwest.多发性硬化症中的新冠病毒病：来自美国太平洋西北地区的初步观察
Neurol Neuroimmunol Neuroinflamm. 2020 May 26;7(5). doi: 10.1212/NXI.0000000000000783. Print 2020 Sep 3.
10
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.初始疾病修饰治疗与随后继发进展性多发性硬化转化的相关性。
JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.
引用本文的文献
1
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.COVID-19 严重程度和多发性硬化症结局：一项全国性、基于登记、匹配队列研究的结果。
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
2
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.COVID-19 大流行期间和大流行后多发性硬化症的管理更新：国际共识声明。
J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7.
3
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.接受B细胞耗竭疗法的患者和体液免疫缺陷状态患者的COVID-19结局：一项范围综述
Pathog Immun. 2021 May 14;6(1):76-103. doi: 10.20411/pai.v6i1.435. eCollection 2021.
4
COVID-19 illness and autoimmune diseases: recent insights.COVID-19 疾病与自身免疫性疾病：最新见解。
Inflamm Res. 2021 Apr;70(4):407-428. doi: 10.1007/s00011-021-01446-1. Epub 2021 Feb 28.
5
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.评估澳大利亚一家多发性硬化症中心的患者及其相关疾病对 COVID-19 大流行期间 DMT 的看法。
Mult Scler Relat Disord. 2020 Nov;46:102516. doi: 10.1016/j.msard.2020.102516. Epub 2020 Sep 16.
本文引用的文献
1
An Italian programme for COVID-19 infection in multiple sclerosis.一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
2
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
3
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?奥瑞珠单抗治疗多发性硬化症患者合并 COVID-19：免疫抑制是否具有保护作用？
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
4
Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.多发性硬化症与感染风险：关于新型冠状病毒COVID-19/SARS-CoV-2威胁的考量
J Neurol. 2020 May;267(5):1567-1569. doi: 10.1007/s00415-020-09822-3.
5
Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.单独隔离或与其他公共卫生措施相结合以控制新冠病毒病：一项快速综述
Cochrane Database Syst Rev. 2020 Apr 8;4(4):CD013574. doi: 10.1002/14651858.CD013574.
6
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.在2019冠状病毒病大流行期间治疗多发性硬化症和视神经脊髓炎谱系障碍。
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
7
Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?新冠病毒感染中针对过度炎症反应的免疫抑制：一把双刃剑？
Lancet. 2020 Apr 4;395(10230):1111. doi: 10.1016/S0140-6736(20)30691-7. Epub 2020 Mar 24.
8
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
9
COVID-19 in Latin America: The implications of the first confirmed case in Brazil.拉丁美洲的新冠疫情：巴西首例确诊病例的影响。
Travel Med Infect Dis. 2020 May-Jun;35:101613. doi: 10.1016/j.tmaid.2020.101613. Epub 2020 Feb 29.
10
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
Zotero 插件